| Drug Name |
Panobinostat |
| Drug ID |
BADD_D02454 |
| Description |
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. |
| Indications and Usage |
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015. |
| Marketing Status |
Not Available |
| ATC Code |
L01XH03 |
| DrugBank ID |
DB06603
|
| KEGG ID |
D10319
|
| MeSH ID |
D000077767
|
| PubChem ID |
6918837
|
| TTD Drug ID |
D0E3SH
|
| NDC Product Code |
73116-101; 73116-100; 73116-102; 0078-0650; 0078-0652; 0078-0651 |
| Synonyms |
Panobinostat | LBH589 | NVP-LBH589 | NVP LBH589 | LBH 589 | Farydak |
